Operative management of colorectal liver metastases

Seminars in Liver Disease

Volumn 33, Issue 3, 2013, Pages 262-272

  Mentha, Gilles ^a   Terraz, Sylvain ^a   Andres, Axel ^a   Toso, Christian ^a   Rubbia Brandt, Laura ^a   Majno, Pietro ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

colorectal liver metastases; long term survival; margin; operative management; reversed approach

Indexed keywords

BEVACIZUMAB; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB;

ANASTOMOSIS LEAKAGE; ARGON PLASMA COAGULATION; ARTICLE; ARTIFICIAL EMBOLISM; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL LIVER METASTASIS; COLORECTAL SURGERY; COMPUTER ASSISTED TOMOGRAPHY; HEMIHEPATECTOMY; HOSPITALIZATION; HUMAN; INTERVENTIONAL RADIOLOGY; INTESTINE TUMOR; LIVER; LIVER RESECTION; LONG TERM SURVIVAL; METASTASIS RESECTION; MICROMETASTASIS; OVERALL SURVIVAL; PEROPERATIVE ECHOGRAPHY; PORTAL VEIN; PORTAL VEIN THROMBOSIS; POSTOPERATIVE COMPLICATION; PRIMARY TUMOR; PRIORITY JOURNAL; RECTUM SURGERY; SURGICAL MORTALITY;

CHEMOTHERAPY, ADJUVANT; COLECTOMY; COLORECTAL NEOPLASMS; EMBOLIZATION, THERAPEUTIC; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; NEOADJUVANT THERAPY; NEOPLASM, RESIDUAL; RADIOGRAPHY, INTERVENTIONAL; TREATMENT OUTCOME;

EID: 84882269600     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0033-1351785     Document Type: Article

References (87)

1. Khatri V. P., Petrelli N. J., Belghiti J. Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit? J Clin Oncol: 2005; 23 33 8490 8499
2. Mentha G., Majno P., Terraz S., et al. Treatment strategies for the management of advanced colorectal liver metastases detected synchronously with the primary tumour. Eur J Surg Oncol: 2007; 33 02 S76 S83
3. Folprecht G., Gruenberger T., Bechstein W. O., et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol: 2010; 11 1 38 47
4. Nordlinger B., Sorbye H., Glimelius B., et al. EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet: 2008; 371 9617 1007 1016
5. Stremitzer S., Stift J., Gruenberger B., et al. KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab. Br J Surg: 2012; 99 11 1575 1582
6. Belghiti J., Hiramatsu K., Benoist S., Massault P. F., Sauvanet A., Farges O. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg: 2000; 191 1 38 46
7. Strong R. W., Lynch S. V., Wall D. R., Ong T. H. The safety of elective liver resection in a special unit. Aust N Z J Surg: 1994; 64 8 530 534
8. Sharma A., Deeb A. P., Iannuzzi J. C., Rickles A. S., Monson J. R., Fleming F. J. Tobacco smoking and postoperative outcomes after colorectal surgery. Ann Surg: 2012;. epub ahead of print
9. Andres A., Toso C., Moldovan B., et al. Complications of elective liver resections in a center with low mortality: a simple score to predict morbidity. Arch Surg: 2011; 146 11 1246 1252
10. Choti M. A., Bowman H. M., Pitt H. A., et al. Should hepatic resections be performed at high-volume referral centers? J Gastrointest Surg: 1998; 2 1 11 20
11. Fong Y., Gonen M., Rubin D., Radzyner M., Brennan M. F. Long-term survival is superior after resection for cancer in high-volume centers. Ann Surg: 2005; 242 4 540 544, discussion 544-547
12. Chowdhury M. M., Dagash H., Pierro A. A systematic review of the impact of volume of surgery and specialization on patient outcome. Br J Surg: 2007; 94 2 145 161
13. Csikesz N. G., Simons J. P., Tseng J. F., Shah S. A. Surgical specialization and operative mortality in hepato-pancreatico-biliary (HPB) surgery. J Gastrointest Surg: 2008; 12 9 1534 1539
14. Berney T., Mentha G., Morel P. Total vascular exclusion of the liver for the resection of lesions in contact with the vena cava or the hepatic veins. Br J Surg: 1998; 85 4 485 488
15. Kooby D. A., Stockman J., Ben-Porat L., et al. Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases. Ann Surg: 2003; 237 6 860 869, discussion 869-870
16. de Jong M. C., Mayo S. C., Pulitano C., et al. Repeat curative intent liver surgery is safe and effective for recurrent colorectal liver metastasis: results from an international multi-institutional analysis. J Gastrointest Surg: 2009; 13 12 2141 2151
17. Zorzi D., Mullen J. T., Abdalla E. K., et al. Comparison between hepatic wedge resection and anatomic resection for colorectal liver metastases. J Gastrointest Surg: 2006; 10 1 86 94
18. Dhir M., Lyden E. R., Wang A., Smith L. M., Ullrich F., Are C. Influence of margins on overall survival after hepatic resection for colorectal metastasis: a meta-analysis. Ann Surg: 2011; 254 2 234 242
19. Pawlik T. M., Scoggins C. R., Zorzi D., et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg: 2005; 241 5 715 722, discussion 722-724
20. Holdhoff M., Schmidt K., Diehl F., et al. Detection of tumor DNA at the margins of colorectal cancer liver metastasis. Clin Cancer Res: 2011; 17 11 3551 3557
21. Mentha G., Terraz S., Morel P., et al. Dangerous halo after neoadjuvant chemotherapy and two-step hepatectomy for colorectal liver metastases. Br J Surg: 2009; 96 1 95 103
22. Maru D. M., Kopetz S., Boonsirikamchai P., et al. Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases. Am J Surg Pathol: 2010; 34 9 1287 1294
23. Falcone A., Ricci S., Brunetti I., et al. Gruppo Oncologico Nord Ovest Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol: 2007; 25 13 1670 1676
24. Seium Y., Stupp R., Ruhstaller T., et al. Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study. Ann Oncol: 2005; 16 5 762 766
25. Saltz L. B., Clarke S., Díaz-Rubio E., et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol: 2008; 26 12 2013 2019
26. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med: 2004; 350 23 2335 2342
27. Vauthey J. N., Pawlik T. M., Ribero D., et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol: 2006; 24 13 2065 2072
28. Rubbia-Brandt L., Audard V., Sartoretti P., et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol: 2004; 15 3 460 466
29. Wicherts D. A., de Haas R. J., Andreani P., et al. Impact of portal vein embolization on long-term survival of patients with primarily unresectable colorectal liver metastases. Br J Surg: 2010; 97 2 240 250
30. Adam R., De Gramont A., Figueras J., et al. Jean-Nicolas Vauthey of the EGOSLIM (Expert Group on OncoSurgery management of LIver Metastases) group The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist: 2012; 17 10 1225 1239
31. Kishi Y., Madoff D. C., Abdalla E. K., et al. Is embolization of segment 4 portal veins before extended right hepatectomy justified? Surgery: 2008; 144 5 744 751
32. Goéré D., Farges O., Leporrier J., Sauvanet A., Vilgrain V., Belghiti J. Chemotherapy does not impair hypertrophy of the left liver after right portal vein obstruction. J Gastrointest Surg: 2006; 10 3 365 370
33. Elias D., De Baere T., Roche A., Mducreux, Leclere J., Lasser P. During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma. Br J Surg: 1999; 86 6 784 788
34. Hoekstra L. T., van Lienden K. P., Doets A., Busch O. RC, Gouma D. J., van Gulik T. M. Tumor progression after preoperative portal vein embolization. Ann Surg: 2012; 256 5 812 817, discussion 817-818
35. Weng M., Zhang Y., Zhou D., et al. Radiofrequency ablation versus resection for colorectal cancer liver metastases: a meta-analysis. PLoS ONE: 2012; 7 9 e45493
36. Adam R., Laurent A., Azoulay D., Castaing D., Bismuth H. Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors. Ann Surg: 2000; 232 6 777 785
37. Narita M., Oussoultzoglou E., Jaeck D., et al. Two-stage hepatectomy for multiple bilobar colorectal liver metastases. Br J Surg: 2011; 98 10 1463 1475
38. Tanaka K., Hiroshima Y., Nakagawa K., et al. Two-stage hepatectomy with effective perioperative chemotherapy does not induce tumor growth or growth factor expression in liver metastases from colorectal cancer. Surgery: 2013; 153 2 179 188
39. Brouquet A., Abdalla E. K., Kopetz S., et al. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol: 2011; 29 8 1083 1090
40. Muratore A., Zimmitti G., Ribero D., Mellano A., Viganò L., Capussotti L. Chemotherapy between the first and second stages of a two-stage hepatectomy for colorectal liver metastases: should we routinely recommend it? Ann Surg Oncol: 2012; 19 4 1310 1315
41. Turrini O., Ewald J., Viret F., Sarran A., Goncalves A., Delpero J. R. Two-stage hepatectomy: who will not jump over the second hurdle? Eur J Surg Oncol: 2012; 38 3 266 273
42. Stella M., Dupre A., Chabaud S., et al. A comparative study of patients with and without associated digestive surgery in a two-stage hepatectomy setting. Langenbecks Arch Surg: 2012; 397 8 1289 1296
43. Karoui M., Vigano L., Goyer P., et al. Combined first-stage hepatectomy and colorectal resection in a two-stage hepatectomy strategy for bilobar synchronous liver metastases. Br J Surg: 2010; 97 9 1354 1362
44. Schnitzbauer A. A., Lang S. A., Goessmann H., et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg: 2012; 255 3 405 414
45. Alvarez F. A., Ardiles V., Sanchez Claria R., Pekolj J., de Santibañes E. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): tips and tricks. J Gastrointest Surg: 2013; 17 4 814 821
46. Aloia T. A., Vauthey J. N. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): what is gained and what is lost? Ann Surg: 2012; 256 3 e9, author reply e16-e19
47. Dokmak S., Belghiti J. Which limits to the "ALPPSo" approach? Ann Surg: 2012; 256 3 e6, author reply e16-e17
48. Lehmann K., Rickenbacher A., Weber A., Pestalozzi B. C., Clavien P. A. Chemotherapy before liver resection of colorectal metastases: friend or foe? Ann Surg: 2012; 255 2 237 247
49. Adam R., Bhangui P., Poston G., et al. Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases? Ann Surg: 2010; 252 5 774 787
50. Benoist S., Pautrat K., Mitry E., Rougier P., Penna C., Nordlinger B. Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases. Br J Surg: 2005; 92 9 1155 1160
51. Muratore A., Zorzi D., Bouzari H., et al. Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy? Ann Surg Oncol: 2007; 14 2 766 770
52. Thelen A., Jonas S., Benckert C., et al. Simultaneous versus staged liver resection of synchronous liver metastases from colorectal cancer. Int J Colorectal Dis: 2007; 22 10 1269 1276
53. Reddy S. K., Pawlik T. M., Zorzi D., et al. Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol: 2007; 14 12 3481 3491
54. Weber J. C., Bachellier P., Oussoultzoglou E., Jaeck D. Simultaneous resection of colorectal primary tumour and synchronous liver metastases. Br J Surg: 2003; 90 8 956 962
55. Chua H. K., Sondenaa K., Tsiotos G. G., Larson D. R., Wolff B. G., Nagorney D. M. Concurrent vs. staged colectomy and hepatectomy for primary colorectal cancer with synchronous hepatic metastases. Dis Colon Rectum: 2004; 47 8 1310 1316
56. Martin R. CG II, Augenstein V., Reuter N. P., Scoggins C. R., McMasters K. M. Simultaneous versus staged resection for synchronous colorectal cancer liver metastases. J Am Coll Surg: 2009; 208 5 842 850, discussion 850-852
57. Kaibori M., Iwamoto S., Ishizaki M., et al. Timing of resection for synchronous liver metastases from colorectal cancer. Dig Dis Sci: 2010; 55 11 3262 3270
58. Capussotti L., Vigano' L., Ferrero A., Lo Tesoriere R., Ribero D., Polastri R. Timing of resection of liver metastases synchronous to colorectal tumor: proposal of prognosis-based decisional model. Ann Surg Oncol: 2007; 14 3 1143 1150
59. de Haas R. J., Adam R., Wicherts D. A., et al. Comparison of simultaneous or delayed liver surgery for limited synchronous colorectal metastases. Br J Surg: 2010; 97 8 1279 1289
60. Slesser A. AP, Simillis C., Goldin R., Brown G., Mudan S., Tekkis P. P. A meta-analysis comparing simultaneous versus delayed resections in patients with synchronous colorectal liver metastases. Surg Oncol: 2013; 22 1 36 47
61. Chiappa A., Biffi R., Bertani E., et al. Surgical outcomes after total mesorectal excision for rectal cancer. J Surg Oncol: 2006; 94 3 182 193, discussion 181
62. Tran C. L., Udani S., Holt A., Arnell T., Kumar R., Stamos M. J. Evaluation of safety of increased time interval between chemoradiation and resection for rectal cancer. Am J Surg: 2006; 192 6 873 877
63. Matthiessen P., Hallböök O., Rutegård J., Simert G., Sjödahl R. Defunctioning stoma reduces symptomatic anastomotic leakage after low anterior resection of the rectum for cancer: a randomized multicenter trial. Ann Surg: 2007; 246 2 207 214
64. Salmenkylä S., Kouri M., Osterlund P., et al. Does preoperative radiotherapy with postoperative chemotherapy increase acute side-effects and postoperative complications of total mesorectal excision? Report of the randomized Finnish rectal cancer trial. Scand J Surg: 2012; 101 4 275 282
65. Mantion G., Panis Y. Mortalité et morbidité en chirurgie colorectale. Rapport de l'Association de Chirurgie 2003. Paris, France l'Association de Chirurgie: 2003;. Monographie, Arnette Edition. September 2003
66. O'Reilly M. S., Holmgren L., Shing Y., et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell: 1994; 79 2 315 328
67. O'Reilly M. S., Holmgren L., Chen C., Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med: 1996; 2 6 689 692
68. Peeters C. F., de Waal R. M., Wobbes T., Westphal J. R., Ruers T. J. Outgrowth of human liver metastases after resection of the primary colorectal tumor: a shift in the balance between apoptosis and proliferation. Int J Cancer: 2006; 119 6 1249 1253
69. Fong Y., Fortner J., Sun R. L., Brennan M. F., Blumgart L. H. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg: 1999; 230 3 309 318, discussion 318-321
70. Mala T., Bohler G., Mathisen O., Bergan A., Soreide O. Hepatic resection for colorectal metastases: can preoperative scoring predict patient outcome? World J Surg: 2002; 26 11 1348 1353
71. Andres A., Majno P. E., Morel P., et al. Improved long-term outcome of surgery for advanced colorectal liver metastases: reasons and implications for management on the basis of a severity score. Ann Surg Oncol: 2008; 15 1 134 143
72. Mann C. D., Metcalfe M. S., Leopardi L. N., Maddern G. J. The clinical risk score: emerging as a reliable preoperative prognostic index in hepatectomy for colorectal metastases. Arch Surg: 2004; 139 11 1168 1172
73. Mentha G., Majno P. E., Andres A., Rubbia-Brandt L., Morel P., Roth A. D. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg: 2006; 93 7 872 878
74. Gervaz P., Rubbia-Brandt L., Andres A., et al. Neoadjuvant chemotherapy in patients with stage IV colorectal cancer: a comparison of histological response in liver metastases, primary tumors, and regional lymph nodes. Ann Surg Oncol: 2010; 17 10 2714 2719
75. O'Rourke T. R., Welsh F. K., Rees M. Comment on: Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg: 2006; 93 872 878
76. Verhoef C., van der Pool A. EM, Nuyttens J. J., Planting A. ST, Eggermont A. MM, de Wilt J. HW. The "liver-first approacho" for patients with locally advanced rectal cancer and synchronous liver metastases. Dis Colon Rectum: 2009; 52 1 23 30
77. de Jong M. C., van Dam R. M., Maas M., et al. The liver-first approach for synchronous colorectal liver metastasis: a 5-year single-centre experience. HPB (Oxford): 2011; 13 10 745 752
78. Brouquet A., Mortenson M. M., Vauthey J. N., et al. Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy? J Am Coll Surg: 2010; 210 6 934 941
79. Mentha G., Roth A. D., Terraz S., et al. 'Liver first' approach in the treatment of colorectal cancer with synchronous liver metastases. Dig Surg: 2008; 25 6 430 435
80. Andres A., Toso C., Adam R., et al. A survival analysis of the liver-first reversed management of advanced simultaneous colorectal liver metastases: a LiverMetSurvey-based study. Ann Surg: 2012; 256 5 772 778, discussion 778-779
81. Adam R., Wicherts D. A., de Haas R. J., et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol: 2008; 26 10 1635 1641
82. Blazer D. G. III, Kishi Y., Maru D. M., et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol: 2008; 26 33 5344 5351
83. Elias D., Youssef O., Sideris L., et al. Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy. J Surg Oncol: 2004; 86 1 4 9
84. Benoist S., Brouquet A., Penna C., et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol: 2006; 24 24 3939 3945
85. van Kessel C. S., Buckens C. F., van den Bosch M. A., van Leeuwen M. S., van Hillegersberg R., Verkooijen H. M. Preoperative imaging of colorectal liver metastases after neoadjuvant chemotherapy: a meta-analysis. Ann Surg Oncol: 2012; 19 9 2805 2813
86. Gaujoux S., Goéré D., Dumont F., et al. Complete radiological response of colorectal liver metastases after chemotherapy: what can we expect? Dig Surg: 2011; 28 2 114 120
87. Rubbia-Brandt L., Giostra E., Brezault C., et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol: 2007; 18 2 299 304